Strategy of prevention of hepatitis B virus recurrence after liver transplantation

[Objective] To investigate the prevention and treatment of hepatitis B virus (HBV) recurrence after liver transplantation on HBV-related diseases. [Methods] Retrospective analysis the effect of 40 cases liver transplantation on HBV-related diseases performed during 2000, 10 to 2003, 10 in our hospital with combination use of HBIG and Lamivudine. [Results] 40 patients were followed up 12~36 months. Two cases died of carcinoma recurrence at 8 month and 13 month respectively. 31 cases could not detect HBsAg, HBeAg and HBV-DNA in serum after two weeks of operation, six in which detected HBsAg positive during 2~9 month, because of cease Lamivudine and HBIG treatment for economic reason. Their liver function recovered quickly, HBsAg, HBeAg and HBV-DNA became negative after treated by Lamivudine and HBIG. Three patients′ HBsAg, HBeAg and HBV-DNA were still positive 4 months after liver transplantation, but HBV-DNA declined below 104 copies/ml , HBsAg became negative and liver function kept well. [Conclusions] Combination use of Lamivudine and HBIG for prevention and treatment HBV recurrence is well done on HBV-related diseases after liver transplantation.